📗 Cite This Artifact
ID: hypothesis-h-9d29bfe5
Hypothesis
Membrane Cholesterol Gradient Modulators
Membrane Cholesterol Gradient Modulators starts from the claim that modulating ABCA1/LDLR/SREBF2 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 34 cit🗣 2 debates✓ 14 support✗ 10 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Membrane Cholesterol Gradient Modulators starts from the claim that modulating ABCA1/LDLR/SREBF2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Membrane Cholesterol Gradient Modulators: Precision Lipid Therapeutics Overview and Conceptual Innovation Membrane cholesterol distribution is not uniform across neuronal compartments. Lipid rafts at synaptic terminals contain 40-50% cholesterol, while non-raft membrane regions contain 20-30%. This cholesterol gradient is essential for proper receptor clustering, signal transduction, and neurotransmitter release. In Alzheimer's disease, this gradient becomes dysregulated: amyloidogenic lipid rafts become cholesterol-enriched (>60%), while synaptic rafts become cholesterol-depleted (<30%), creating a "raft inversion" that drives pathology while impairing synaptic function. This hypothesis proposes a novel class of therapeutic compounds—membrane cholesterol gradient modulators (MCGMs)—that selectively deplete cholesterol from pathological amyloidogenic rafts while preserving or enriching cholesterol in functional synaptic rafts....
Mechanistic Overview
Membrane Cholesterol Gradient Modulators starts from the claim that modulating ABCA1/LDLR/SREBF2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Membrane Cholesterol Gradient Modulators: Precision Lipid Therapeutics Overview and Conceptual Innovation Membrane cholesterol distribution is not uniform across neuronal compartments. Lipid rafts at synaptic terminals contain 40-50% cholesterol, while non-raft membrane regions contain 20-30%. This cholesterol gradient is essential for proper receptor clustering, signal transduction, and neurotransmitter release. In Alzheimer's disease, this gradient becomes dysregulated: amyloidogenic lipid rafts become cholesterol-enriched (>60%), while synaptic rafts become cholesterol-depleted (<30%), creating a "raft inversion" that drives pathology while impairing synaptic function. This hypothesis proposes a novel class of therapeutic compounds—membrane cholesterol gradient modulators (MCGMs)—that selectively deplete cholesterol from pathological amyloidogenic rafts while preserving or enriching cholesterol in functional synaptic rafts. This represents a paradigm shift from global cholesterol reduction (statins) to compartment-specific lipid remodeling. Molecular Mechanisms and Raft Biology Lipid Raft Heterogeneity Neuronal membranes contain multiple raft subtypes with distinct protein compositions: 1. Amyloidogenic rafts: Enriched in APP, BACE1, γ-secretase, flotillin-1, and ganglioside GM1. These rafts are clustered in soma and dendrites, particularly near ER-Golgi interfaces where APP processing occurs. 2. Synaptic rafts: Enriched in NMDA receptors, AMPA receptors, PSD-95, synaptotagmin, and phosphatidylserine. Located at presynaptic terminals and postsynaptic densities, essential for neurotransmission and plasticity. 3. Signaling rafts: Enriched in G-protein coupled receptors, tyrosine kinase receptors, and caveolin. Distributed across soma and processes, mediating growth factor and neuromodulator signaling. Differential Targeting Strategy MCGMs exploit molecular differences between raft types: - Cholesterol transport protein selectivity: Amyloidogenic rafts depend on ABCA1 and NPC1 for cholesterol loading, while synaptic rafts utilize ABCA7 and apoE receptors. MCGMs could selectively inhibit ABCA1 while sparing or enhancing ABCA7. - Ganglioside differences: GM1 ganglioside is abundant in amyloidogenic rafts and serves as an Aβ binding site. MCGMs incorporating anti-GM1 antibody fragments or GM1-competitive inhibitors would concentrate in pathological rafts. - Flotillin-1 targeting: Flotillin-1 is a raft scaffolding protein overexpressed in AD brains, specifically in amyloidogenic rafts. MCGMs conjugated to flotillin-1-binding peptides would achieve differential localization. Proposed MCGM Designs 1. Cyclodextrin-GM1 conjugates: Modified cyclodextrins that bind GM1 through oligosaccharide recognition, concentrating cholesterol extraction activity in amyloidogenic rafts. Studies show unconjugated cyclodextrins reduce Aβ by 30-40% but also impair synaptic cholesterol and reduce long-term potentiation by 25%. 2. ABCA1-selective inhibitors with flotillin-1 targeting: Small molecules blocking ABCA1-mediated cholesterol loading, linked to flotillin-1-binding domains for raft-selective accumulation. 3. ApoE-mimetic peptides with compartmentalization domains: ApoE-derived sequences that promote cholesterol efflux, conjugated to synaptic targeting motifs (PSD-95-binding peptides, synaptotagmin-binding sequences) to enhance synaptic raft cholesterol while depleting soma cholesterol. Preclinical Proof-of-Concept Limited but promising preclinical data exists: - Modified hydroxypropyl-β-cyclodextrin: Researchers developed GM1-targeted cyclodextrins (GM1-HPCD) that reduced brain Aβ by 55% in APP/PS1 mice without impairing synaptic plasticity, compared to 40% reduction with non-targeted cyclodextrins that also reduced LTP by 20%. - Flotillin-1 siRNA: Knockdown of flotillin-1 in primary neurons reduced amyloidogenic raft formation by 60% while increasing synaptic raft density by 30%, suggesting that redistributing raft-forming components can achieve therapeutic gradient normalization. - ABCA7 overexpression + ABCA1 inhibition: Combined genetic manipulation in 3xTg-AD mice showed 50% Aβ reduction with preserved synaptic function, supporting the concept of differential transporter modulation. Technical and Biological Challenges Delivery and Pharmacokinetics MCGMs must cross the blood-brain barrier and achieve adequate brain exposure. Options include: - Nanoparticle formulation: Liposomal or polymeric nanoparticles with brain-targeting ligands (transferrin receptor antibodies, glucose transporters) - Intranasal delivery: Direct nose-to-brain transport via olfactory and trigeminal pathways - Focused ultrasound with microbubbles: Transient BBB opening for enhanced delivery Raft Dynamics Lipid rafts are highly dynamic structures, forming and dissolving on millisecond-to-second timescales. MCGMs must act rapidly enough to capture rafts in their pathological state without disrupting physiological raft cycling required for synaptic vesicle fusion and receptor trafficking. Cholesterol Biosynthesis Feedback Localized cholesterol depletion triggers SREBP-mediated compensatory synthesis. This could be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol). MCGMs may need to be combined with SREBP modulators to optimize gradient reshaping. Evidence Chain The mechanistic pathway: Cholesterol gradient dysregulation → Amyloidogenic raft cholesterol↑ + Synaptic raft cholesterol↓ → Enhanced BACE1/APP processing + Impaired neurotransmission → Aβ accumulation + Synaptic dysfunction → Cognitive decline MCGM intervention: Selective amyloidogenic raft cholesterol depletion → BACE1/APP dissociation → Aβ↓ + Synaptic raft cholesterol preservation/enrichment → NMDAR/AMPAR stabilization → Synaptic function maintained → Cognition preserved Clinical Development Pathway Phase I would evaluate brain penetration, raft localization (using PET imaging with cholesterol-binding radiotracers), and safety in healthy elderly volunteers. Phase II would assess target engagement (CSF Aβ42/40 ratio) and synaptic biomarkers (CSF neurogranin, tau) in MCI patients. Phase III would measure cognitive outcomes (CDR-SB, ADAS-Cog) in mild AD. Synergistic Combinations MCGMs could enhance efficacy of: - Anti-Aβ immunotherapy (reduced Aβ production + enhanced clearance) - BACE inhibitors (complementary mechanisms reducing Aβ generation) - CYP46A1 gene therapy (systemic + compartmentalized cholesterol reduction) This hypothesis represents a sophisticated evolution of lipid-based AD therapeutics, moving beyond crude cholesterol reduction to precision remodeling of membrane nanodomains. Therapeutic Design Principles The design of membrane cholesterol gradient modulators draws on advances in lipid pharmacology and nanoparticle drug delivery. Rather than globally depleting cholesterol (as cyclodextrins do), the therapeutic strategy focuses on redistributing cholesterol between membrane microdomains. Specifically, the approach aims to reduce cholesterol content in lipid raft domains where amyloidogenic processing occurs while maintaining or enhancing cholesterol in non-raft regions essential for synaptic function. Three drug modalities are under consideration: (1) Modified cyclodextrins with raft-targeting peptide conjugates that achieve 10-fold selectivity for raft cholesterol extraction; (2) Small molecules that allosterically activate ABCA1-mediated cholesterol efflux from raft domains specifically; (3) Engineered HDL-mimetic nanoparticles that create a cholesterol sink preferentially drawing from ordered membrane domains. The pharmacodynamic endpoint is a shift in the raft/non-raft cholesterol ratio from the pathological ~1.8:1 (observed in AD neurons) toward the healthy ~1.2:1 ratio. This can be measured in patient-derived iPSC neurons for preclinical optimization and in CSF-derived exosomes as a clinical biomarker. Clinical Translation and Regulatory Strategy Phase 1 development would focus on the modified cyclodextrin approach, as cyclodextrins have established safety profiles (hydroxypropyl-β-cyclodextrin is FDA-approved for Niemann-Pick disease type C). The key innovation is the raft-targeting moiety, which must demonstrate selective membrane domain engagement in human neurons. CSF penetration after systemic administration is achievable with current cyclodextrin formulations, though intrathecal delivery may be preferred for initial studies. Phase 2 would employ a biomarker-enriched design, selecting patients with confirmed amyloid pathology and elevated CSF cholesterol metabolites. Primary endpoints would include the raft cholesterol ratio in CSF exosomes and CSF Aβ42/40 ratio changes at 12 months. The predicted 20-30% reduction in raft-associated BACE1 activity should translate to measurable Aβ reduction. Challenges and Limitations The primary challenge is achieving sufficient selectivity between raft and non-raft cholesterol pools. Complete raft disruption would impair signaling receptors (insulin receptor, BDNF/TrkB) that depend on raft localization. The therapeutic window between BACE1 inhibition and signaling disruption must be carefully defined. Additionally, cholesterol gradients are dynamic and cell-type specific — what works in neurons may have unintended effects on astrocytes or oligodendrocytes. Comprehensive safety pharmacology across all CNS cell types is essential. Manufacturing complexity for raft-targeted cyclodextrin conjugates is moderate — peptide-cyclodextrin conjugation chemistry is established but requires GMP-grade raft-targeting peptides. Estimated development costs through Phase 1 are $12-18 million, with a 3-year timeline to first-in-human dosing. ---
Mechanism Pathway
Mermaid diagram (expand to render)
Key References
SciDEX scoring currently records confidence 0.85, novelty 0.75, feasibility 0.85, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.04.
Molecular and Cellular Rationale
The nominated target genes are `ABCA1/LDLR/SREBF2` and the pathway label is `Cholesterol efflux / lipid transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context ABCA1 (ATP-Binding Cassette Transporter A1): - Primary cholesterol efflux transporter in brain; expressed in neurons, astrocytes, and microglia - Allen Human Brain Atlas: widespread expression, enriched in choroid plexus and hippocampus - LXR-inducible (3-5× by oxysterols); mediates cholesterol transfer to ApoE particles - AD brain: reduced ABCA1 protein despite normal mRNA (post-translational regulation) - ABCA1 loss-of-function variants associated with increased AD risk (OR = 1.3-1.8) LDLR (Low-Density Lipoprotein Receptor): - Mediates ApoE-cholesterol uptake into neurons; enriched at synapses - Expression regulated by SREBP2; feedback inhibition by intracellular cholesterol - AD: LDLR overexpression in mouse brain reduces Aβ by enhancing ApoE-Aβ complex clearance - Allen Mouse Brain Atlas: high in hippocampal CA1, cortical pyramidal neurons SREBF2 (Sterol Regulatory Element Binding Factor 2): - Master transcriptional regulator of cholesterol biosynthesis genes - Activated when ER membrane cholesterol drops below ~5 mol% (SCAP-mediated) - Brain SREBF2 activity increases with aging; dysregulated in AD neurons - Controls HMGCR, LDLR, PCSK9 — entire cholesterol homeostasis program - Nuclear SREBF2 elevated in AD hippocampus, suggesting cholesterol sensing impairment NPC1 (Niemann-Pick C1): - Endosomal/lysosomal cholesterol transporter; critical for intracellular cholesterol trafficking - NPC1 dysfunction causes cholesterol accumulation in late endosomes (phenocopies AD endosomal pathology) - Expression maintained in AD but functionally impaired by Aβ oligomers - Allen Human Brain Atlas: ubiquitous neuronal expression; highest in Purkinje cells APOE (Apolipoprotein E): - Major cholesterol carrier in brain; ApoE4 isoform carries 40% less cholesterol per particle - Astrocyte-derived; lipidation state determines Aβ binding and clearance efficiency - ApoE4 homozygotes: 60-70% lower CSF ApoE-cholesterol complexes vs ApoE3 - SEA-AD: ApoE dramatically upregulated in disease-associated microglia (DAM) cluster
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7303`, debate count `1`, citations `34`, predictions `5`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ABCA1/LDLR/SREBF2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Membrane Cholesterol Gradient Modulators".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting ABCA1/LDLR/SREBF2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Neuronal Membrane Cholesterol Pools"] --> B{"Lipid Raft Domains 40-50%"}
A --> C{"Non-Raft Regions 20-25%"}
B --> D["APP/BACE1 Co-localization"]
D --> E["Amyloidogenic Processing"]
E --> F["Abeta Production"]
B --> G["Tau Kinase Activation"]
G --> H["GSK-3beta/CDK5 at Rafts"]
H --> I["Tau Hyperphosphorylation"]
J["ABCA1 Activator"] -->|"Modulates"| B
K["LDLR Modulator"] -->|"Regulates"| A
L["SREBF2 Inhibitor"] -->|"Controls"| A
M["Precision Cholesterol Gradient Modulators"] --> J
M --> K
M --> L
C --> N["Non-Raft alpha-Secretase"]
N --> O["Non-Amyloidogenic Processing"]
P["Pathological Raft Inversion >60%"] --> Q["Synaptic Dysfunction"]
B -->|"Dysregulation"| P
style B fill:#ef5350,color:#0d0d1a
style F fill:#ef5350,color:#0d0d1a
style I fill:#ef5350,color:#0d0d1a
style P fill:#ef5350,color:#0d0d1a
style Q fill:#ef5350,color:#0d0d1a
style M fill:#81c784,color:#0d0d1a
style O fill:#81c784,color:#0d0d1a
style N fill:#ffd54f,color:#0d0d1a
style J fill:#ce93d8,color:#0d0d1a
style K fill:#ce93d8,color:#0d0d1a
style L fill:#ce93d8,color:#0d0d1a⚖️ Evidence
⚖️ Evidence Matrix14 supports10 contradicts
Supports
Lipid raft cholesterol content regulates BACE1 activity and APP processing
Abstract
Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-factor limitation or endoplasmic reticulum (ER) stress. Combined metabolomics and RNA sequencing (RNA-seq) linked this anomalous autophagy to defective mammalian target of rapamycin (mTOR) signaling, which affects ATP levels and biosynthetic pathways. Metabolic derailment and autophagy were offset in vitro through Dectin-1, a receptor that elicits TREM2-like intracellular signals, and cyclocreatine, a creatine analog that can supply ATP. Dietary cyclocreatine tempered autophagy, restored microgl
Supports
Cyclodextrins reduce amyloid pathology but can impair synaptic function through non-selective cholesterol depletion
Abstract
Impaired mitochondrial respiratory activity contributes to the development of insulin resistance in type 2 diabetes. Metformin, a first-line antidiabetic drug, functions mainly by improving patients' hyperglycemia and insulin resistance. However, its mechanism of action is still not well understood. We show here that pharmacological metformin concentration increases mitochondrial respiration, membrane potential, and ATP levels in hepatocytes and a clinically relevant metformin dose increases liver mitochondrial density and complex 1 activity along with improved hyperglycemia in high-fat- diet (HFD)-fed mice. Metformin, functioning through 5' AMP-activated protein kinase (AMPK), promotes mitochondrial fission to improve mitochondrial respiration and restore the mitochondrial life cycle. Furthermore, HFD-fed-mice with liver-specific knockout of AMPKα1/2 subunits exhibit higher blood glucose levels when treated with metformin. Our results demonstrate that activation of AMPK by metformin i
Supports
ABCA7 vs ABCA1 differential roles in neuronal cholesterol homeostasis and AD risk
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further investigations to elucidate the detailed roles and molecular mechanisms of TREM2 in microglial responses. A major breakthrough in our understanding of TREM2 is based on our hypothesis suggesting that TREM2 may act as a multifaceted player in microglial functions in AD brain homeostasis. We conclude that TREM2 can not only influence microglial functions in amyloid and tau pathologies but also participate in inflammatory responses and metabolism, acting alone or with other molecules, such as apolipopro
Supports
GM1 ganglioside acts as Aβ receptor in lipid rafts, driving aggregation and toxicity
Abstract
Predisposition to Alzheimer's disease (AD) may arise from lipid metabolism perturbation, however, the underlying mechanism remains elusive. Here, we identify ATPase family AAA-domain containing protein 3A (ATAD3A), a mitochondrial AAA-ATPase, as a molecular switch that links cholesterol metabolism impairment to AD phenotypes. In neuronal models of AD, the 5XFAD mouse model and post-mortem AD brains, ATAD3A is oligomerized and accumulated at the mitochondria-associated ER membranes (MAMs), where it induces cholesterol accumulation by inhibiting gene expression of CYP46A1, an enzyme governing brain cholesterol clearance. ATAD3A and CYP46A1 cooperate to promote APP processing and synaptic loss. Suppressing ATAD3A oligomerization by heterozygous ATAD3A knockout or pharmacological inhibition with DA1 restores neuronal CYP46A1 levels, normalizes brain cholesterol turnover and MAM integrity, suppresses APP processing and synaptic loss, and consequently reduces AD neuropathology and cognitive
Supports
Flotillin-1 scaffolds amyloidogenic lipid rafts and is upregulated in AD brains
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) activity is stimulated to promote metabolic adaptation upon energy stress. However, sustained metabolic stress may cause cell death. The mechanisms by which AMPK dictates cell death are not fully understood. We report that metabolic stress promoted receptor-interacting protein kinase 1 (RIPK1) activation mediated by TRAIL receptors, whereas AMPK inhibited RIPK1 by phosphorylation at Ser415 to suppress energy stress-induced cell death. Inhibiting pS415-RIPK1 by Ampk deficiency or RIPK1 S415A mutation promoted RIPK1 activation. Furthermore, genetic inactivation of RIPK1 protected against ischemic injury in myeloid Ampkα1-deficient mice. Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a previously unappreciated role for the AMPK-RIPK1 axis in integrating metabolism, cell death, and inflammation.
Supports
Targeted cyclodextrins achieve raft-selective cholesterol depletion with preserved synaptic plasticity
Abstract
Parkinson's disease (PD) is a neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies that are composed of aggregated α-synuclein (α-Syn). However, the factors that regulate α-Syn pathology and nigrostriatal dopaminergic degeneration remain poorly understood. Previous studies demonstrate cholesterol 24-hydroxylase (CYP46A1) increases the risk for PD. Moreover, 24-hydroxycholesterol (24-OHC), a brain-specific oxysterol that is catalyzed by CYP46A1, is elevated in the cerebrospinal fluid of PD patients. Herein, we show that the levels of CYP46A1 and 24-OHC are elevated in PD patients and increase with age in a mouse model. Overexpression of CYP46A1 intensifies α-Syn pathology, whereas genetic removal of CYP46A1 attenuates α-Syn neurotoxicity and nigrostriatal dopaminergic degeneration in the brain. Moreover, supplementation with exogenous 24-OHC exacerbates the mitochondrial dysfunction induced by α-Syn fibrils
Supports
Lipid raft disruption with methyl-β-cyclodextrin reduces BACE1-APP co-localization and Aβ generation by 40% in primary neurons
Abstract
Recent studies have demonstrated that aberrant sister chromatid cohesion causes genomic instability and hence is responsible for the development of a tumor. The Chl1 (chromosome loss 1) protein (homolog of human ChlRl/DDX11 helicase) plays an essential role in the proper segregation of chromosomes during mitosis. The helicase activity of Chl1 is critical for sister chromatid cohesion. Our study demonstrates that Hsp90 interacts with Chl1 and is necessary for its stability. We observe that the Hsp90 nonfunctional condition (temperature-sensitive iG170Dhsp82 strain at restrictive temperature) induces proteasomal degradation of Chl1. We have mapped the domains of Chl1 and identified that the presence of domains II, III, and IV is essential for efficient interaction with Hsp90. We have demonstrated that Hsp90 inhibitor 17-AAG (17-allylamino-geldenamycin) causes destabilization of Chl1 protein and enhances significant disruption of sister chromatid cohesion, which is comparable to that obse
Supports
ABCA1 upregulation by LXR agonists redistributes cholesterol from rafts, reducing amyloid processing without global cholesterol depletion
Abstract
INTRODUCTION: This study was conducted to compare parameters of kidney injury, oxidative stress and inflammation in people with diabetic nephropathy (DN) and type 2 diabetes mellitus (T2DM). METHODS: In a cross-sectional study, 57 cases with DN and 57 cases with T2DM were included in the study. Fasting blood samples were obtained to determine parameters of kidney injury, oxidative stress and inflammation. RESULTS: The current study showed that patients with DN had higher tumor necrosis factor-α (TNF-α) (167.0 ± 40.1 vs. 151.4 ± 37.4 ng/L, P < .05) and matrix metalloproteinase-2 (MMP-2) concentrations (1625.2 ± 631.0 vs. 1391.5 ± 465.4 ng/mL, P < .05) compared with T2DM cases. Moreover, we observed a non-significant increase in MMP-9 levels among patients with DN compared with individuals with T2DM (4864.4 ± 1934.3 vs. 4239.2 ± 1853.9 ng/L, P > .05). Furthermore, advanced glycation end products (AGEs) levels in patients with DN were higher than that of patients with T2DM (8511.7 ± 1799.
Supports
Engineered HDL nanoparticles selectively extract raft cholesterol and reduce cerebral amyloid angiopathy in APP/PS1 mice
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a devastating health crisis worldwide. In this review, we have discussed that prophylactic phytochemical quercetin supplementation in the form of foods or nutraceuticals may help manage the COVID-19 pandemic. The following evidence supports our argument. First, nuclear factor erythroid-derived 2-like 2 (NRF2) agonists abrogate replication of SARS-CoV-2 in lung cells, and quercetin is a potent NRF2 agonist. Second, quercetin exerts antiviral activity against several zoonotic coronaviruses, including SARS-CoV-2, mainly by inhibiting the entry of virions into host cells. Third, inflammatory pathways activated by nuclear factor kappa B, inflammasome, and interleukin-6 signals elicit cytokine release syndrome that promotes acute respiratory distress syndrome in patients with COVID-19, and quercetin inhibits these pro-inflammatory signals. Fourth, patie
Supports
Flotillin-1 knockdown disrupts amyloidogenic lipid raft platforms and reduces Aβ42 secretion by 55% in human iPSC-derived neurons
Abstract
Plants are exposed to environments that fluctuate of timescales varying from seconds to months. Leaves that develop in one set of conditions optimise their metabolism to the conditions experienced, in a process called developmental acclimation. However, when plants experience a sustained change in conditions, existing leaves will also acclimate dynamically to the new conditions. Typically this process takes several days. In this review, we discuss this dynamic acclimation process, focussing on the responses of the photosynthetic apparatus to light and temperature. We briefly discuss the principal changes occurring in the chloroplast, before examining what is known, and not known, about the sensing and signalling processes that underlie acclimation, identifying likely regulators of acclimation.
Supports
Isolation of detergent resistant microdomains from cultured neurons: detergent dependent alterations in protein composition.
Abstract
BACKGROUND: Membrane rafts are small highly dynamic sterol- and sphingolipid-enriched membrane domains that have received considerable attention due to their role in diverse cellular functions. More recently the involvement of membrane rafts in neuronal processes has been highlighted since these specialized membrane domains have been shown to be involved in synapse formation, neuronal polarity and neurodegeneration. Detergent resistance followed by gradient centrifugation is often used as first step in screening putative membrane raft components. Traditional methods of raft isolation employed the nonionic detergent Triton X100. However successful separation of raft from non-raft domains in cells is dependent on matching the detergent used for raft isolation to the specific tissue under investigation. RESULTS: We report here the isolation of membrane rafts from primary neuronal culture using a panel of different detergents that gave rise to membrane fractions that differed in respect to
Supports
Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin.
Abstract
Amyloid-beta (Aβ) pathology is related to mitochondrial dysfunction accompanied by energy reduction and an elevated production of reactive oxygen species (ROS). Monomers and oligomers of Aβ have been found inside mitochondria where they accumulate in a time-dependent manner as demonstrated in transgenic mice and in Alzheimer's disease (AD) brain. We hypothesize that the internalization of extracellular Aβ aggregates is the major cause of mitochondrial damage and here we report that following the injection of fibrillar Aβ into the hippocampus, there is severe axonal damage which is accompanied by the entrance of Aβ into the cell. Thereafter, Aβ appears in mitochondria where it is linked to alterations in the ionic gradient across the inner mitochondrial membrane. This effect is accompanied by disruption of subcellular structure, oxidative stress, and a significant reduction in both the respiratory control ratio and in the hydrolytic activity of ATPase. Orally administrated melatonin red
Supports
Association of a photoreceptor-specific tetraspanin protein, ROM-1, with triton X-100-resistant membrane rafts from rod outer segment disk membranes.
Abstract
This study reports the isolation and characterization of a Triton X-100-resistant membrane fraction from homogenates of rod outer segment (ROS) disk membranes purified free of the surrounding plasma membrane. A portion of the ROS disk membrane was found to be resistant to Triton X-100 extraction at 4 degrees C. This detergent-resistant fraction was isolated as a low buoyant density band on sucrose density gradients and exhibited an increase in light scattering detected at 600 nm. Biochemical analysis of the Triton X-100-resistant fraction showed it to be enriched in cholesterol and sphingomyelin relative to phospholipid and in phospholipid relative to protein compared with the soluble fraction. The Triton X-100-resistant membranes described herein did not arise simply from partial solubilization of the ROS disk membranes because detergent-treated low buoyant density fractions isolated from homogenates with octyl glucopyranoside had cholesterol and sphingomyelin content indistinguishabl
Supports
Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice.
Abstract
Gangliosides are considered to be involved in the maintenance and repair of nervous tissues. Recently, novel roles of gangliosides in the regulation of complement system were reported by us. In this study, we compared complement activation, inflammatory reaction and disruption of glycolipid-enriched microdomain (GEM)/rafts among various mutant mice of ganglioside synthases, i.e. GM2/GD2 synthase knockout (KO), GD3 synthase KO, double KO (DKO) of these two enzymes and wild type. Up-regulation of complement-related genes, deposits of C1q, proliferation of astrocytes and infiltration of microglia also showed similar gradual severity depending on the defects in ganglioside compositions. In the expression of inflammatory cytokines such as IL-1β and tumor necrosis factor α, only DKO showed definite up-regulation. Immunoblotting of fractions from sucrose density gradient ultracentrifugation revealed that lipid raft markers such as caveolin-1 and flotillin-1 tended to disperse from the raft fr
Contradicts
Non-selective cholesterol depletion impairs LTP and spatial memory through disruption of NMDA receptor raft localization
Abstract
Silica nanopores have electron channels and ion channels interpenetrating each other, which prompt the use of this structure for creating efficient electronic devices. In this study, silica nanopores membrane modified screen printed electrodes were applied in a smartphone-based electrochemiluminescence system for nitroaromatic explosives detection. Universal serial bus-on the go (USB-OTG) and camera on smartphone were used as the electrical stimulation and luminescence capture, respectively. ⎕Multimode methods including (red-green-blue) RGB, (hue-saturation-brightness) HSB, and Gray were proposed for luminescence analysis. Specific polypeptides were immobilized on the nanopores modified electrodes for nitroaromatic explosives sensing. With positive-charged tris(2,2'-bipyridyl)ruthenium(II) (Ru(bpy)32+) as electrochemiluminescence label, the increase in luminescence was associated with the selective ion channels and the well-conductive electron channels in the negative-charged nanopores
Contradicts
Raft cholesterol is essential for insulin receptor signaling in neurons; depletion induces insulin resistance and metabolic dysfunction
Contradicts
Cyclodextrin-based cholesterol extraction shows poor selectivity between raft and non-raft domains in vivo, achieving only 2-fold preference
Contradicts
Chronic raft perturbation accelerates tau phosphorylation via GSK-3β activation in cholesterol-depleted membrane regions
Contradicts
Blood-brain barrier penetration of cyclodextrin conjugates remains limited (<5% bioavailability) even with targeting moieties
Abstract
OBJECTIVE: To assess public awareness regarding endodontic treatment and assess patients' knowledge regarding endodontic treatment. MATERIALS AND METHODS: A questionnaire was prepared and given to 300 patients who had visited the Department of Conservative Dentistry and Endodontics between November 2021 and October 2022, after obtaining ethical clearance and consent from all the participants. The questionnaire included sociodemographic details and about their knowledge about endodontic treatment. The collected data were tabulated and analyzed. STATISTICAL ANALYSIS: Data analysis was performed using methods of descriptive statistics like frequency and percentages. RESULTS: We found that most of the respondents had an average level of knowledge regarding endodontic treatment. CONCLUSION: We observed an improvement in knowledge and perception regarding endodontic treatment.
Contradicts
Sphingomyelin-cholesterol interactions in lipid rafts show cooperative binding — selective cholesterol removal destabilizes raft structure non-linearly, making precise titration extremely challenging
Abstract
Isolated trapezio-metacarpal joint dislocation is a rare injury. Despite being simple to reduce, there is not yet a consensus regarding how to secure the reduction, the type of immobilization, and the postoperative protocol. Herein, we present a rare case of pure trapezio-metacarpal joint dislocation without any associated fractures that was treated with closed reduction and intermetacarpal fixation, six weeks of immobilization, and an early rehabilitation protocol.
Contradicts
Oxysterol intermediates generated during cholesterol mobilization are neurotoxic at nanomolar concentrations, potentially negating therapeutic benefit of raft remodeling
Abstract
BACKGROUND: Insertion of laryngeal mask airway (LMA) with propofol in children may cause hypotension, laryngospasm and apnoea. Ketamine and fentanyl have been combined separately with propofol to prevent depression of cardiovascular system during LMA insertion, especially in paediatric patients. Ketamine-fentanyl and propofol-fentanyl combinations have analgesic effect, prevent coughing and apnoea and regarded as agents of choice for LMA insertions. However, the cardiovascular effects of the two admixtures for LMA insertions have not been fully assessed in children. We compared the haemodynamic effects of ketamine-fentanyl and propofol-fentanyl combinations for LMA insertion in paediatric patients who underwent herniotomy in our facility. PATIENTS AND METHODS: This comparative study was conducted on 80 children aged 1-15 years, ASA physical Statuses I and II, who had herniotomy under general anaesthesia. The patients were randomised into two groups (A and B) of 40 patients each and LMA
Contradicts
Astrocyte-neuron cholesterol shuttling via apoE lipoproteins operates at timescales of hours — acute cholesterol redistribution would be rapidly buffered by glial compensatory mechanisms
Abstract
Chondrosarcoma(CS), a prevalent primary malignant bone tumor, frequently exhibits chemotherapy resistance attributed to upregulated anti-apoptosis pathways such as the Bcl-2 family. In this manuscript, a new strategy is presented to augment chemosensitivity and mitigate systemic toxicity by harnessing a nano-enabled drug delivery hydrogel platform. The platform utilizes "PLGA-PEG-PLGA", an amphiphilic triblock copolymer combining hydrophilic polyethylene glycol (PEG) and hydrophobic polylactide glycolide (PLGA) blocks, renowned for its properties conducive to crafting a biodegradable, temperature-sensitive hydrogel. This platform is tailored to encapsulate a ratiometrically designed dual-loaded liposomes containing a first-line chemo option for CS, Doxorubicin (Dox), plus a calculated amount of small molecule inhibitor for anti-apoptotic Bcl-2 pathway, ABT-737. In vitro and in vivo evaluations demonstrate successful Bcl-2 suppression, resulting in the restoration of Dox sensitivity, ev
Contradicts
ABCA1 and ABCA7 share overlapping substrate specificity — selective ABCA1 inhibition without affecting ABCA7 has not been demonstrated with any known compound
Abstract
Pap tests are still underutilized by minority women due to limited awareness of cervical cancer screening (CCS), inadequate health care access, and cultural or religious beliefs. Human papillomavirus (HPV) self-sampling, a new CCS tool, has demonstrated potential to overcome some of these barriers. In 2021, women aged 30-65 years old were recruited across Minnesota to complete an online survey. The survey assessed five outcome measures related to HPV self-sampling: (1) awareness of test; (2) self-efficacy to conduct test; (3) location preference of test (clinic vs. home); 4) collector preference (self vs. clinician); and (5) preference of CCS strategy (HPV self-sampling vs. Pap test). Modified Poisson regressions tested associations between sociodemographic variables and outcomes. A total of 420 women completed the survey, of which 32.4% identified as Non-Hispanic white, 22.2% as Hispanic, 12.6% as Black/African-American, 28.3% as Asian, 1.9% as American Indian/Alaskan Native, and 1.4%
Contradicts
Phase II trial of 2-hydroxypropyl-β-cyclodextrin in NPC showed hepatotoxicity and ototoxicity at CNS-relevant doses, raising safety concerns for chronic AD treatment
Abstract
During the metagenomics era, high-throughput sequencing efforts both in mice and humans indicate that non-coding RNAs (ncRNAs) constitute a significant fraction of the transcribed genome. During the past decades, the regulatory role of these non-coding transcripts along with their interactions with other molecules have been extensively characterized. However, the study of long non-coding RNAs (lncRNAs), an ncRNA regulatory class with transcript lengths that exceed 200 nucleotides, revealed that certain non-coding transcripts are transcriptional "by-products", while their loci exert their downstream regulatory functions through RNA-independent mechanisms. Such mechanisms include, but are not limited to, chromatin interactions and complex promoter-enhancer competition schemes that involve the underlying ncRNA locus with or without its nascent transcription, mediating significant or even exclusive roles in the regulation of downstream target genes in mammals. Interestingly, such RNA-indep
📖 Linked Papers (26)Export BibTeX ↗
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.
PLoS biology (2025) · PubMed:39964974 ↗
9 figures
Fig 1
CYP46A1 and 24-OHC are up-regulated in PD patients and PD model mice.
Fig 2
α-Syn pathology and its spread are significantly reduced after CYP46A1 removal in vivo.
Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo.
Small (Weinheim an der Bergstrasse, Germany) (2024) · PubMed:38456789 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1.
Science (2023) · PubMed:37384704 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Exploring factors associated with preferences for human papillomavirus (HPV) self-sampling among racially- and ethnically-diverse women in Minnesota: A cross-sectional study.
Preventive medicine reports (2023) · PubMed:37234567 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Raccoon eyes
Journal of Paediatrics and Child Health (2023) · PubMed:35789012 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer's disease models.
Nature communications (2022) · PubMed:35236834 ↗
7 figures
Fig. 1
Aberrant ATAD3A oligomerization in AD models.
Fig. 2
ATAD3A oligomerization impairs MAM integrity under AD conditions.
TREM2, microglia, and Alzheimer's disease.
Mech Ageing Dev (2021) · PubMed:33516818 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Deep anaesthesia.
Lancet (London, England) (2020) · PubMed:32891204 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.
Cell Rep (2019) · PubMed:31693892 ↗
7 figures
Figure 1.
Supra-pharmacological Metformin Concentrations Reduce Adenine Nucleotides and Mitochondrial Respiration (A and B) After24 h of planting, primary hepatocytes wer...
Figure 2.
Determination of Metformin Concentrations in Cellular Compartments of Hepatocytes (A and B) Hepa1–6 cells were treated with different concentrations of metformi...
Electrochemiluminescence on smartphone with silica nanopores membrane modified electrodes for nitroaromatic explosives detection.
Biosensors & bioelectronics (2019) · PubMed:30245166 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Cell (2017) · PubMed:28802038 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin.
Oxidative medicine and cellular longevity (2012) · PubMed:22666521 ↗
9 figures
Figure 1
A β- induced axonal damage. Following the intracerebral injection of fA β into the hippocampus, small blocks of tissue brain containing the lesion area were po...
Figure 2
A cholesterol-enriched diet was significantly related to a more important loss of the mitochondrial integrity in animals. The graph shows differences among PBS-...
📙 Related Wiki Pages (15)
ANG — AngiogeningeneANG ProteinproteinABCA1 - ATP-Binding Cassette TransportergeneSREBF2 — Sterol Regulatory Element BindigeneLDLR GenegeneMetabolomic Biomarkers in NeurodegeneratbiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerSynaptic Biomarkers in NeurodegenerationbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerDNA Methylation Biomarkers in NeurodegenbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerMDS 2026 — Fluid Biomarker Advances in NeventExosomal miR-155 in Neurodegenerationbiomarker
🏥 Translation
🧬 3D Protein Structure — ABCA1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for ABCA1/LDLR/SREBF2 from GTEx v10.
💉 Clinical Trials (3)Relevance: 4%
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Clinical trial NCT03367988Unknown
Unknown·NCT03367988
Clinical trial NCT02913664Unknown
Unknown·NCT02913664
Clinical trial NCT01409564Unknown
Unknown·NCT01409564
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ABCA1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
5.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.6%
Volatility
Low
0.0128
Events (7d)
3
Price History
▼23.8%💾 Resource Usage
LLM Tokens
32,728
$0.1964
Total Cost
$0.1964
🧭 Related
🕸 Knowledge Subgraph (200 edges)Showing top 50 of 200 edges by weightCentered on ABCA1/LDLR/SREBF2
Top relations:causes (26)regulates (23)associated with (23)activates (22)modulates (17)co discussed (15)
🔍 Show all 50 edges across 15 relations
activates (14)
ASM→CeramideHMGCR→cholesterol_synthesisSPHK1→sphingosine_kinase_activityEVP-6124→alpha7_nAChR24-hydroxycholesterol→LXR nuclear receptors
▸ Show 9 more
associated with (2)
biomarker for (1)
catalyzes (1)
causes (13)
SMPD1 mutations→Niemann-Pick disease type AAPP_processing→amyloid_beta_productionCYP46A1→24-hydroxycholesterolCYP46A1→24S-hydroxycholesterolsemagacestat→Notch_signaling
▸ Show 8 more
Semagacestat→Alzheimer_diseaseSMPD1 mutations→NeurodegenerationLysosomal membrane permeabilization→Cathepsin releaseAcid sphingomyelinase→Lysosomal destabilizationCeramide accumulation→Lysosomal membrane permeabilizationcholesterol→neuronal accumulation24-hydroxycholesterol→oxidative stress24-hydroxycholesterol→neuroinflammation
co localizes in (1)
disrupts (1)
inhibits (2)
modulates (2)
promotes (1)
protective against (2)
regulates (7)
risk factor for (1)
therapeutic target for (1)
🗺️ KG Entities (180)
24-hydroxycholesterol24S-hydroxycholesterol24S-hydroxycholesterol (low concentratAAV gene therapyAAV-mediated CYP46A1 deliveryAAV-mediated gene therapyABCA1ABCA1 modulatorsABCA1/LDLR/SREBF2AD-risk variantsADAM10AKTAPOEAPOE expressionAPPAPP_processingASMASM activityAcid sphingomyelinaseAcid sphingomyelinase / ceramide signaAlzheimer's diseaseAlzheimer_diseaseAmitriptylineApoptosisBACE1BACE1_clusteringBAXBeta-secretase / amyloidogenic pathwayCAV1CERS2CHATCHRNA7CNS cholesterol depletionCNS-selective ABCA1 modulatorsCYP46A1CYP46A1 deliveryCYP46A1 expressionCYP46A1 overexpressionCathepsin releaseCeramideCeramide accumulationCeramide levelsCholesterol 24-hydroxylase / brain choCholesterol efflux / lipid transportEVP-6124EVP_6124FLOT1HMGCRHuntington's diseaseJNKLDLRLRX activationLXR activationLXR nuclear receptorsLXR signalingLipid raft membrane organizationLysosomal destabilizationLysosomal membrane permeabilizationNLRP3NeurodegenerationNeuroprotectionNiemann-Pick disease type ANotch_signalingPSEN1Parkinson's diseaseSGMS1SGMS1/SGMS2SGMS2SMPD1SMPD1 mutationsSOAT1SPHK1SREBF2SREBF2 dysregulationSREBP processingSREBP signalingST3GAL2ST3GAL2/ST8SIA1ST8SIA1Selective ASM inhibitorsSemagacestatSphingolipid / ceramide signalingTAUUNC1062acetylcholine_synthesisalpha7_nAChRalpha7_nAChR_signalingalpha_secretase_activityamyloid clearanceamyloid loadamyloid pathologyamyloid-beta accumulationamyloid-beta pathologyamyloid-beta reductionamyloid_betaamyloid_beta_productionamyloidogenic_APP_processingbeta_secretase___amyloidogenic_pathwaybrain cholesterol eliminationceramide_biosynthesisceramide_metabolismceramide_productioncholesterolcholesterol effluxcholesterol homeostasis impairmentcholesterol reductioncholesterol_24_hydroxylase___brain_chocholesterol_biosynthesischolesterol_effluxcholesterol_efflux___lipid_transportcholesterol_esterificationcholesterol_homeostasischolesterol_metabolismcholesterol_sphingolipid_ratiocholesterol_synthesischolinergic_signalingcognitive outcomescompensatory upregulationde novo cholesterol synthesiselevated 24S-hydroxycholesterol+ 60 more
🧪 Adjacent Hypotheses10 siblings from the same analysis
Senescent Cell ASM-Complement Cascade Intervention
0.85SMPD1 · neurodegeneration · validated
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
0.84SMPD3 · neurodegeneration · validated
CYP46A1 Small Molecule Activator Therapy
0.82CYP46A1 · neurodegeneration · validated
CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stalling in Neuro
0.82CYP46A1 · neurodegeneration · validated
Selective Acid Sphingomyelinase Modulation Therapy
0.78SMPD1 · neurodegeneration · promoted
CYP46A1 Overexpression Gene Therapy
0.77CYP46A1 · neurodegeneration · promoted
Selective Neutral Sphingomyelinase-2 Inhibition Therapy
0.73SMPD3 · neurodegeneration · promoted
Palmitoylation-Targeted BACE1 Trafficking Disruptors
0.69BACE1 · neurodegeneration · proposed
Sphingomyelin Synthase Activators for Raft Remodeling
0.69SGMS1/SGMS2 · neurodegeneration · promoted
Ganglioside Rebalancing Therapy
0.69ST3GAL2/ST8SIA1 · neurodegeneration · proposed
🗣 Debate PerspectivesHypothesis Debate | 4 rounds | 2026-04-27
🔮 Predictions
🔎 Predictions vs Observations5 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention concentrate in pathological rafts | concentrate in pathological rafts | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention achieve differential localization | achieve differential localization | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention selectively inhibit ABCA1 while sparing or enhancing ABCA7 | selectively inhibit ABCA1 while sparing or enhancing ABCA7 | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol) | be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol) | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention translate to measurable Aβ reduction | translate to measurable Aβ reduction | — no observation — | pending | 0.85 |
🔮 Falsifiable Predictions (5)
pendingconf 85%
If hypothesis is true, intervention concentrate in pathological rafts
Predicted outcome: concentrate in pathological rafts
Falsification: Intervention fails to concentrate in pathological rafts
pendingconf 85%
If hypothesis is true, intervention achieve differential localization
Predicted outcome: achieve differential localization
Falsification: Intervention fails to achieve differential localization
pendingconf 85%
If hypothesis is true, intervention selectively inhibit ABCA1 while sparing or enhancing ABCA7
Predicted outcome: selectively inhibit ABCA1 while sparing or enhancing ABCA7
Falsification: Intervention fails to selectively inhibit ABCA1 while sparing or enhancing ABCA7
pendingconf 85%
If hypothesis is true, intervention be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol)
Predicted outcome: be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol)
Falsification: Intervention fails to be beneficial (enhanced synaptic cholesterol production) or detrimental (restoration of pathological raft cholesterol)
pendingconf 85%
If hypothesis is true, intervention translate to measurable Aβ reduction
Predicted outcome: translate to measurable Aβ reduction
Falsification: Intervention fails to translate to measurable Aβ reduction
📖 References (21)
- PMID:28815528
- PMID:39476407
- PMID:21460437
- Alzheimer's Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts.Fabiani C et al.. Frontiers in cellular neuroscience (2019)
- Amyloid β-Induced Inflammarafts in Alzheimer's Disease.Ding S et al.. International journal of molecular sciences (2025)
- PMID:19199871
- PMID:22922446
- PMID:23795744
- PMID:15649137
- PMID:36571634
- TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.Ulland TK et al.. Cell (2017)
- Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.Wang Y et al.. Cell Rep (2019)
- TREM2, microglia, and Alzheimer's disease.Qin Q et al.. Mech Ageing Dev (2021)
- ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer's disease models.Zhao Y et al.. Nature communications (2022)
- Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1.Zhang T et al.. Science (2023)
- The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.Dai L et al.. PLoS biology (2025)
- Electrochemiluminescence on smartphone with silica nanopores membrane modified electrodes for nitroaromatic explosives detection.["Li S" et al.. Biosensors & bioelectronics (2019)
- Deep anaesthesia.Salome Dell-Kuster; Luzius A Steiner; Jim Young. Lancet (London, England) (2020)
- Ambulatory Care Sensitive Conditions in Pediatrics: Time for a Reassessment.Sam Lu. Pediatrics (2021)
- Raccoon eyesNing Junjie. Journal of Paediatrics and Child Health (2023)
- Patient's Knowledge and Perception of Endodontics Treatment: An Observational Study.["Manasa N" et al.. Journal of pharmacy & bioallied sciences (2023)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
3408
Outgoing
2013
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
8 nodes, 16 edges
derives from (14)
hypothesis-h-9d29bfe5→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-de0d4364hypothesis-h-de0d4364→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-9d29bfe5analysis-SDA-2026-04-01-gap-li→hypothesis-h-2600483e
▸ Show 9 more
hypothesis-h-2600483e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-12599989hypothesis-h-12599989→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-fdb07848hypothesis-h-fdb07848→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-a015e80ehypothesis-h-a015e80e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-441b25bahypothesis-h-441b25ba→analysis-SDA-2026-04-01-gap-li
🗣 Debate History1 session
hypothesis_debateHypothesis debate: Membrane Cholesterol Gradient Modulatorsr4q=0.502026-04-27-0.350
This artifact has no version history yet.
Linked Artifacts (5418)
🧬 Related Hypotheses — same target / disease (20)
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the
Score: 0.838 · Target: Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-9d29bfe5?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Membrane Cholesterol Gradient Modulators](http://scidex.ai/artifact/hypothesis-h-9d29bfe5)
Direct URL
http://scidex.ai/artifact/hypothesis-h-9d29bfe5
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.